Medpace Holdings’ (MEDP) Hold Rating Reaffirmed at Jefferies Group
Other research analysts also recently issued reports about the company. Wells Fargo & Co. assumed coverage on Medpace Holdings in a research report on Tuesday, September 6th. They set an outperform rating for the company. Robert W. Baird started coverage on Medpace Holdings in a report on Tuesday, September 6th. They issued a neutral rating and a $35.00 price target for the company. Credit Suisse Group AG started coverage on Medpace Holdings in a report on Tuesday, September 6th. They issued an outperform rating and a $35.00 price target for the company. Finally, William Blair reiterated an outperform rating on shares of Medpace Holdings in a report on Tuesday, September 6th. Two research analysts have rated the stock with a hold rating and three have given a buy rating to the company. The stock has a consensus rating of Buy and a consensus target price of $34.17.
Shares of Medpace Holdings (NASDAQ:MEDP) traded up 0.67% during mid-day trading on Tuesday, hitting $30.17. The stock had a trading volume of 4,341 shares. Medpace Holdings has a 12-month low of $26.51 and a 12-month high of $31.35. The stock’s market cap is $984.81 million. The company’s 50 day moving average price is $29.33 and its 200 day moving average price is $29.30.
In other Medpace Holdings news, insider Susan E. Burwig purchased 19,211 shares of the firm’s stock in a transaction that occurred on Wednesday, August 17th. The stock was purchased at an average cost of $29.21 per share, with a total value of $561,153.31. Following the transaction, the insider now owns 1,211 shares in the company, valued at $35,373.31. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO August J. Troendle purchased 869,565 shares of the firm’s stock in a transaction that occurred on Tuesday, August 16th. The shares were acquired at an average cost of $23.00 per share, with a total value of $19,999,995.00. Following the completion of the transaction, the chief executive officer now owns 1,221,416 shares in the company, valued at approximately $28,092,568. The disclosure for this purchase can be found here.
Medpace Holdings Company Profile
Medpace Holdings, Inc is a holding company. The Company operates as a clinical contract research organization (CRO) focused on providing scientifically-driven outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. The Company is focused on conducting clinical trials across therapeutic areas, with focus in cardiology, metabolic disease, oncology, endocrinology, central nervous system (CNS), and Anti-Viral and Anti-Infective (AVAI).
Receive News & Stock Ratings for Medpace Holdings Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medpace Holdings Inc and related stocks with our FREE daily email newsletter.